Dendreon Corp (NASDAQ:DNDN)

CAPS Rating: 2 out of 5

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

Recs

1
Player Avatar TSIF (99.96) Submitted: 5/7/2012 5:19:37 PM : Underperform Start Price: $11.69 DNDN Score: +20.40

Dendreon Corporation continues to struggle getting Provenge marketed at a profit. I expect the bleed the last quarter to continue, especially considering the share price increase from $9 to $12 the last few weeks gave it more altitude to drop from.
(The $7-$14 in early January also shows the volitility and expectations).

The hazards of going it alone in a tough medication market, especially with a drug that is expensive and needs customization. I believe Dendreon could still be a buyout candidate by someone with a better channel already established. This was the intent from the beginning. As such, I don't expect to hold this call very long.

Featured Broker Partners


Advertisement